The Blueprint for Novel Science
Translating Differentiated Biology into Transformational Medicines
Grounded in rigorous science, we are advancing a portfolio of Signal Regulatory Protein (SIRP)-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer.
We are pioneering a new class of precision medicines.
Our novel approach harnesses the unique biology of SIRP to selectively deplete activated, disease-driving immune cells.
We are committed to tackling therapeutic challenges in diseases with critical unmet need and delivering breakthrough for patients.
Our portfolio of SIRP-directed antibodies employs a differentiated mechanism of action with the potential to address the underlying pathology across a broad range of diseases, including some with no approved therapies.
Our experienced team is united by a shared mission to advance innovative science and drive transformational impact for patients.